Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80

Journal of Immunology

Volumn 186, Issue 12, 2011, Pages 6822-6829

  Haile, Samuel T ^a   Bosch, Jacobus J ^a,b   Agu, Nnenna I ^a   Zeender, Annette M ^a   Somasundaram, Preethi ^a   Srivastava, Minu K ^a   Britting, Sabine ^b   Wolf, Julie B ^a   Ksander, Bruce R ^c,d   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; HLA DR ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY;

ANTIGENS, CD; ANTIGENS, CD80; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TRANSFECTION;

EID: 79959541203     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003682     Document Type: Article

References (51)

1. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
2. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
3. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
4. Brown, J. A., D. M. Dorfman, F. R. Ma, E. L. Sullivan, O. Munoz, C. R. Wood, E. A. Greenfield, and G. J. Freeman. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170: 1257-1266. (Pubitemid 36139491)
5. Chen, L. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4: 336-347.
6. Yang, W., H. Li, P. W. Chen, H. Alizadeh, Y. He, R. N. Hogan, and J. Y. Niederkorn. 2009. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest. Ophthalmol. Vis. Sci. 50: 273-280.
7. Latchman, Y. E., S. C. Liang, Y. Wu, T. Chernova, R. A. Sobel, M. Klemm, V. K. Kuchroo, G. J. Freeman, and A. H. Sharpe. 2004. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 101: 10691-10696.
8. Azuma, T., S. Yao, G. Zhu, A. S. Flies, S. J. Flies, and L. Chen. 2008. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111: 3635-3643.
9. Butte, M. J., M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122.
10. Park, J. J., R. Omiya, Y. Matsumura, Y. Sakoda, A. Kuramasu, M. M. Augustine, S. Yao, F. Tsushima, H. Narazaki, S. Anand, et al. 2010. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116: 1291-1298.
11. Hirano, F., K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D. B. Flies, J. S. Lau, G. Zhu, et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65: 1089-1096. (Pubitemid 40216472)
12. Blank, C., J. Kuball, S. Voelkl, H. Wiendl, B. Becker, B. Walter, O. Majdic, T. F. Gajewski, M. Theobald, R. Andreesen, and A. Mackensen. 2006. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer 119: 317-327.
13. Strome, S. E., H. Dong, H. Tamura, S. G. Voss, D. B. Flies, K. Tamada, D. Salomao, J. Cheville, F. Hirano, W. Lin, et al. 2003. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63: 6501-6505. (Pubitemid 37255203)
14. Zhu, X., B. A. Fallert-Junecko, M. Fujita, R. Ueda, G. Kohanbash, E. R. Kastenhuber, H. A. McDonald, Y. Liu, P. Kalinski, T. A. Reinhart, et al. 2010. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol. Immunother. 59: 1401-1409.
15. Wilkie, S., S. E. Burbridge, L. Chiapero-Stanke, A. C. Pereira, S. Cleary, S. J. van der Stegen, J. F. Spicer, D. M. Davies, and J. Maher. 2010. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285: 25538-25544.
16. Iliopoulou, E. G., P. Kountourakis, M. V. Karamouzis, D. Doufexis, A. Ardavanis, C. N. Baxevanis, G. Rigatos, M. Papamichail, and S. A. Perez. 2010. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol. Immunother. 59: 1781-1789.
17. Ma, J., L. Liu, G. Che, N. Yu, F. Dai, and Z. You. 2010. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10: 112.
18. Anderson, C. F., and D. M. Mosser. 2002. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J. Leukoc. Biol. 72: 101-106.
19. Itoh, K., K. Shiiba, Y. Shimizu, R. Suzuki, and K. Kumagai. 1985. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma). J. Immunol. 134: 3124-3129. (Pubitemid 16238282)
20. Scott, P. 1991. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147: 3149-3155.
21. Lee, S. J., B. C. Jang, S. W. Lee, Y. I. Yang, S. I. Suh, Y. M. Park, S. Oh, J. G. Shin, S. Yao, L. Chen, and I. H. Choi. 2006. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 580: 755-762.
22. Dissanayake, S. K., J. A. Thompson, J. J. Bosch, V. K. Clements, P. W. Chen, B. R. Ksander, and S. Ostrand-Rosenberg. 2004. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. 64: 1867-1874. (Pubitemid 38428713)
23. Bosch, J. J., J. A. Thompson, M. K. Srivastava, U. K. Iheagwara, T. G. Murray, M. Lotem, B. R. Ksander, and S. Ostrand-Rosenberg. 2007. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res. 67: 4499-4506. (Pubitemid 46815101)
24. Thompson, J. A., M. K. Srivastava, J. J. Bosch, V. K. Clements, B. R. Ksander, and S. Ostrand-Rosenberg. 2008. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol. Immunother. 57: 389-398.
25. Srivastava, M. K., J. J. Bosch, J. A. Thompson, B. R. Ksander, M. J. Edelman, and S. Ostrand-Rosenberg. 2008. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol. Immunother. 57: 1493-1504.
26. Ostrand-Rosenberg, S., B. A. Pulaski, V. K. Clements, L. Qi, M. R. Pipeling, and L. A. Hanyok. 1999. Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol. Rev. 170: 101-114.
27. Schweitzer, A. N., and A. H. Sharpe. 1998. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J. Immunol. 161: 2762-2771.
28. van Rijt, L. S., N. Vos, M. Willart, A. Kleinjan, A. J. Coyle, H. C. Hoogsteden, and B. N. Lambrecht. 2004. Essential role of dendritic cell CD80/CD86 co-stimulation in the induction, but not reactivation, of TH2 effector responses in a mouse model of asthma. J. Allergy Clin. Immunol. 114: 166-173.
29. Verbik, D. J., T. G. Murray, J. M. Tran, and B. R. Ksander. 1997. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int. J. Cancer 73: 470-478.
30. Marincola, F. M., P. Shamamian, T. B. Simonis, A. Abati, J. Hackett, T. O'Dea, P. Fetsch, J. Yannelli, N. P. Restifo, J. J. Mulé, et al. 1994. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J. Immunother. Emphasis Tumor Immunol. 16: 13-23.
31. Welch, D. R., J. E. Bisi, B. E. Miller, D. Conaway, E. A. Seftor, K. H. Yohem, L. B. Gilmore, R. E. Seftor, M. Nakajima, and M. J. Hendrix. 1991. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int. J. Cancer 47: 227-237.
32. Wang, R. F., S. L. Johnston, G. Zeng, S. L. Topalian, D. J. Schwartzentruber, and S. A. Rosenberg. 1998. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161: 3598-3606.
33. Pauley, R. J., H. D. Soule, L. Tait, F. R. Miller, S. R. Wolman, P. J. Dawson, and G. H. Heppner. 1993. The MCF10 family of spontaneously immortalized human breast epithelial cell lines: models of neoplastic progression. Eur. J. Cancer Prev. 2(Suppl 3): 67-76.
34. Brower, M., D. N. Carney, H. K. Oie, A. F. Gazdar, and J. D. Minna. 1986. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46: 798-806.
35. Thompson, J. A., S. K. Dissanayake, B. R. Ksander, K. L. Knutson, M. L. Disis, and S. Ostrand-Rosenberg. 2006. Tumor cells transduced with the MHC class II transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res. 66: 1147-1154. (Pubitemid 43165984)
36. Schaft, N., J. Dörrie, P. Thumann, V. E. Beck, I. Müller, E. S. Schultz, E. Kämpgen, D. Dieckmann, and G. Schuler. 2005. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J. Immunol. 174: 3087-3097. (Pubitemid 40279731)
37. Doty, R. T., and E. A. Clark. 1996. Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation. J. Immunol. 157: 3270-3279.
38. Doty, R. T., and E. A. Clark. 1998. Two regions in the CD80 cytoplasmic tail regulate CD80 redistribution and T cell costimulation. J. Immunol. 161: 2700-2707.
39. Tseng, S. Y., M. Liu, and M. L. Dustin. 2005. CD80 cytoplasmic domain controls localization of CD28, CTLA-4, and protein kinase Ctheta in the immunological synapse. J. Immunol. 175: 7829-7836.
40. Sagerström, C. G., E. M. Kerr, J. P. Allison, and M. M. Davis. 1993. Activation and differentiation requirements of primary T cells in vitro. Proc. Natl. Acad. Sci. USA 90: 8987-8991.
41. Bosch, J. J., U. K. Iheagwara, S. Reid, M. K. Srivastava, J. Wolf, M. Lotem, B. R. Ksander, and S. Ostrand-Rosenberg. 2010. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8(+) cytotoxic, tumor-specific T cells. Cancer Immunol. Immunother. 59: 103-112.
42. Butte, M. J., V. Peña-Cruz, M. J. Kim, G. J. Freeman, and A. H. Sharpe. 2008. Interaction of human PD-L1 and B7-1. Mol. Immunol. 45: 3567-3572.
43. Orabona, C., U. Grohmann, M. L. Belladonna, F. Fallarino, C. Vacca, R. Bianchi, S. Bozza, C. Volpi, B. L. Salomon, M. C. Fioretti, et al. 2004. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol. 5: 1134-1142.
44. Hirokawa, M., A. Kitabayashi, J. Kuroki, and A. B. Miura. 1995. Signal transduction by B7/BB1 expressed on activated T lymphocytes: cross-linking of B7/ BB1 induces protein tyrosine phosphorylation and synergizes with signalling through T-cell receptor/CD3. Immunology 86: 155-161.
45. Hirokawa, M., J. Kuroki, A. Kitabayashi, and A. B. Miura. 1996. Trans-membrane signaling through CD80 (B7-1) induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation. Immunol. Lett. 50: 95-98.
46. Yamazaki, T., H. Akiba, H. Iwai, H. Matsuda, M. Aoki, Y. Tanno, T. Shin, H. Tsuchiya, D. M. Pardoll, K. Okumura, et al. 2002. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169: 5538-5545. (Pubitemid 35291652)
47. Gong, A. Y., R. Zhou, G. Hu, X. Li, P. L. Splinter, S. P. O'Hara, N. F. LaRusso, G. A. Soukup, H. Dong, and X. M. Chen. 2009. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J. Immunol. 182: 1325-1333.
48. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1: 793-801.
49. Boasso, A., A. W. Hardy, A. L. Landay, J. L. Martinson, S. A. Anderson, M. J. Dolan, M. Clerici, and G. M. Shearer. 2008. PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin. Immunol. 129: 132-144.
50. Meier, A., A. Bagchi, H. K. Sidhu, G. Alter, T. J. Suscovich, D. G. Kavanagh, H. Streeck, M. A. Brockman, S. LeGall, J. Hellman, and M. Altfeld. 2008. Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS 22: 655-658. (Pubitemid 351640601)
51. Ge, W., X. Ma, X. Li, Y. Wang, C. Li, H. Meng, X. Liu, Z. Yu, S. You, and L. Qiu. 2009. B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. Leuk. Res. 33: 948-957.